1-6 of 6
Pascal Pujol
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P4-01-20: Phase IV study evaluating talazoparib in patients with locally advanced or metastatic negative HER2 breast cancer and a somatic or germline BRCA1/2 mutation (ViTAL) – Analysis of cohort 1 according to hormonal receptor status

Delphine Loirat, Marie Duboys de la barre, Jean-Christophe Thery, Ioana Hrab, Christelle Jouannaud, Jean-Loup Mouysset, Laura Salabert, Pauline Soibinet, Audrey Mailliez, Romain Valery, Anne Creisson, Cristian Villanueva, Nadine Dohollou, Jean-david Fumet, Thomas grellety, Nathalie Perez-staub, Emma Lachaier, Aurore Iltis-roux, Miguel delbado, Abeer Najem, Romuald Le Scodan, Elsa Curtit, kais aldabbagh, Pascal Pujol, thibault DE LA MOTTE ROUGE
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P4-01-20.
https://doi.org/10.1158/1538-7445.SABCS22-P4-01-20
Published: 01 March 2023
View article titled, Abstract P4-01-20: Phase IV study evaluating talazoparib in patients with locally advanced or metastatic negative HER2 breast cancer and a somatic or germline BRCA1/2 mutation (ViTAL) – Analysis of cohort 1 according to hormonal receptor status
Journal Articles

Abstract P4-01-04: Phase IV multicenter study evaluating RWE and the safety of talazoparib in patients with locally advanced or metastatic negative HER2 breast cancer and a BRCA1/2 mutation (ViTAL) - Cohort 2: patients treated according to the EMA

Delphine Loirat, Marie Duboys de la barre, Cristian Villanueva, Audrey Mailliez, Nicolas Isambert, Lionel Moreau, Emmanuelle Jacquet, Dominique Spaëth, Anne Creisson, Christelle Jouannaud, Eric Legouffe, Miguel delbado, Laura Deiana, Pauline Soibinet, Ioana Hrab, Thomas grellety, Nadine Dohollou, Raffaele Longo, Jean-Christophe Thery, Jean-david Fumet, Sellam Zineb, Pascal Pujol, thibault DE LA MOTTE ROUGE
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P4-01-04.
https://doi.org/10.1158/1538-7445.SABCS22-P4-01-04
Published: 01 March 2023
View article titled, Abstract P4-01-04: Phase IV multicenter study evaluating RWE and the safety of talazoparib in patients with locally advanced or metastatic negative HER2 breast cancer and a BRCA1/2 mutation (ViTAL) - Cohort 2: patients treated according to the EMA
Journal Articles

Abstract P1-18-28: Phase IV study evaluating effectiveness and safety of talazoparib in patients with locally advanced or metastatic HER2 negative breast cancer and a BRCA1 or BRCA2 mutation (ViTAL)

Delphine Loirat, Marie Duboys de Labarre, Christine Essner, Ioana Hrab, Jean-Christophe Thery, Christelle Jouannaud, Cristian Villanueva, Perrine Vuagnat, Pauline Soibinet-Oudot, Anne Creisson, Audrey Mailliez, Jean-Loup Mouysset, Laura Salabert, Nadine Dohollou, Jean-David Fumet, Thibault De La Motte Rouge, Jean-Michel Vauthier, Maylis Decrop, Pascal Pujol
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-18-28.
https://doi.org/10.1158/1538-7445.SABCS21-P1-18-28
Published: 15 February 2022
View article titled, Abstract P1-18-28: Phase IV study evaluating effectiveness and safety of talazoparib in patients with locally advanced or metastatic HER2 negative breast cancer and a <em>BRCA1</em> or <em>BRCA2</em> mutation (ViTAL)
Journal Articles

Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System

Hélène Tubeuf, Sandrine M. Caputo, Teresa Sullivan, Julie Rondeaux, Sophie Krieger, Virginie Caux-Moncoutier, Julie Hauchard, Gaia Castelain, Alice Fiévet, Laëtitia Meulemans, Françoise Révillion, Mélanie Léoné, Nadia Boutry-Kryza, Capucine Delnatte, Marine Guillaud-Bataille, Linda Cleveland, Susan Reid, Eileen Southon, Omar Soukarieh, Aurélie Drouet, Daniela Di Giacomo, Myriam Vezain, Françoise Bonnet-Dorion, Violaine Bourdon, Hélène Larbre, Danièle Muller, Pascal Pujol, Fátima Vaz, Séverine Audebert-Bellanger, Chrystelle Colas, Laurence Venat-Bouvet, Angela R. Solano, Dominique Stoppa-Lyonnet, Claude Houdayer, Thierry Frebourg, Pascaline Gaildrat, Shyam K. Sharan, Alexandra Martins
Journal: Cancer Research
Cancer Res (2020) 80 (17): 3593–3605.
https://doi.org/10.1158/0008-5472.CAN-20-0895
Published: 02 September 2020
View article titled, Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using <em>BRCA2</em> Exon 3 as a Model System
Open the PDF for Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using <em>BRCA2</em> Exon 3 as a Model System in another window
Includes: Supplementary data
Journal Articles

Involvement of Estrogen Receptor β in Ovarian Carcinogenesis

Aurélie Bardin, Pascale Hoffmann, Nathalie Boulle, Dionyssios Katsaros, Françoise Vignon, Pascal Pujol, Gwendal Lazennec
Journal: Cancer Research
Cancer Res (2004) 64 (16): 5861–5869.
https://doi.org/10.1158/0008-5472.CAN-04-0552
Published: 16 August 2004
View article titled, Involvement of Estrogen Receptor β in Ovarian Carcinogenesis
Open the PDF for Involvement of Estrogen Receptor β in Ovarian Carcinogenesis in another window
Journal Articles

Differential Expression of Estrogen Receptor-α and -β Messenger RNAs as a Potential Marker of Ovarian Carcinogenesis

Pascal Pujol, Jean-Marc Rey, Philippe Nirde, Pascal Roger, Marguerite Gastaldi, François Laffargue, Henri Rochefort, Thierry Maudelonde
Journal: Cancer Research
Cancer Res (1998) 58 (23): 5367–5373.
Published: 01 December 1998
View article titled, Differential Expression of Estrogen Receptor-α and -β Messenger RNAs as a Potential Marker of Ovarian Carcinogenesis
Open the PDF for Differential Expression of Estrogen Receptor-α and -β Messenger RNAs as a Potential Marker of Ovarian Carcinogenesis in another window